Blockchain Registration Transaction Record

HeartBeam Completes Enrollment in HEADSTART-ACS Study

HeartBeam completes enrollment in HEADSTART-ACS study, evaluating its 3D ECG for heart attack detection. Results expected in 2027; pivotal U.S. study planned.

This news matters because it signals progress toward a portable, patient-friendly alternative to traditional 12-lead ECGs for detecting heart attacks. If validated, HeartBeam’s 3D ECG technology could enable faster, more accessible cardiac monitoring outside hospitals, potentially saving lives through earlier detection. The completion of enrollment in HEADSTART-ACS, combined with the ALIGN-ACS pilot, brings HeartBeam closer to a pivotal U.S. study and eventual regulatory clearance, which could reshape how acute coronary syndrome is diagnosed in emergency and community settings. For investors, the milestone de-risks the clinical pathway and highlights the company’s growing evidence base.